Memory chips power a vast spectrum of medical technologies, from imaging and diagnostic systems to patient monitors, infusion pumps, ventilators, and surgical robotics. AdvaMed estimates that 75 percent to 80 percent of medtech products, excluding personal protective equipment and consumables, use memory chips. 

As artificial intelligence, cloud computing, and data-center growth drive global demand, medtech companies are facing shortages, longer lead times, allocation limits, and sharp price increases. These disruptions can delay access to the technologies hospitals, clinicians, and patients rely on every day. 

Why the shortage matters 

Memory and storage prices have risen sharply, and industry forecasts suggest supply-demand imbalances may persist well into 2027. 

Recent news coverage has underscored that these constraints are affecting sectors beyond consumer electronics and artificial intelligence infrastructure. An August 10 New York Times article identified medical technology among the industries facing memory chip shortages, noting that rising demand from data centers is increasing competition for the same components used in medical equipment. 

Recent AdvaMed survey results show the breadth of the challenge across the medtech industry. Seventy-five percent of respondents reported memory chip-related constraints, 88 percent reported price increases, and 63 percent reported supplier allocation challenges or limited availability of specific components. Looking ahead, 63 percent said they are uncertain whether they will be able to procure sufficient memory chips, or products incorporating memory chips, to avoid supply chain disruptions, while 56 percent reported being very concerned about overall memory chip supply chain stability. 

Companies are experiencing constraints across several categories of memory and storage technologies, including high-speed memory used to run device software and data processing, flash memory used for long-term storage, removable and embedded storage products, and mature components that remain important because many regulated medical technologies have long product lifecycles. 

Unique challenges for medical technology 

Medtech represents only a small share of global memory demand — around 1 to 2 percent — but its products are indispensable across hospitals, clinics, laboratories, and home-care settings. The sector is especially vulnerable because medical technologies often have longer lifecycles, depend on specific and specialized components, and operate within rigorous regulatory and quality frameworks. 

Substituting components is rarely quick. To ensure patient safety and product effectiveness, changes may require validation, testing, documentation, quality review, and regulatory processes, so even available alternatives can take months or years to implement. 

In contrast to many technology sectors that can rapidly transition to newer hardware platforms, medtech manufacturers often must support products already deployed throughout health care systems for many years. That makes the continuity of supply especially important. 

Impact on manufacturing and innovation 

Lead times for some key components have increased substantially, with companies reporting that certain components now take months longer to obtain than they did under normal supply conditions. Supply constraints can delay production, trigger unplanned redesigns, and complicate long-term product planning. 

For medical technologies, redesign is not simply a procurement decision. Even when an alternative component is available, manufacturers may need to complete engineering assessments, supplier qualification, software or hardware validation, quality-system documentation, risk analysis, and regulatory assessments to determine whether the change affects safety or effectiveness. Depending on the nature of the modification, FDA review or authorization may be required before the redesigned product can be deployed to patients. These safeguards are necessary to protect patient safety and product performance, but they also mean supply disruptions can slow manufacturing timelines and the pace of innovation. 

Patient care at risk 

Memory chip constraints are beginning to affect technologies used in diagnosis, monitoring, and treatment. If chip shortages persist, they could disrupt continuity of care, complicate clinical decision-making, and affect patient outcomes, particularly in high-acuity or resource-constrained settings. 

These disruptions could also increase pressure on hospitals and health systems already managing constrained resources. When critical technologies are delayed or harder to obtain, the effects can extend beyond manufacturers to clinicians, providers, and patients. 

Why health care should be prioritized 

Because memory components support products used to diagnose, monitor, and treat patients, disruptions can extend well beyond commercial impacts. Health care should be prioritized in memory allocation, product transitions, and supply planning. 

Medtech’s memory needs are comparatively modest, so targeted supplier actions can help protect patient care while requiring only a limited share of overall capacity. 

AdvaMed’s call to memory suppliers 

AdvaMed encourages memory chip suppliers to recognize medtech as a priority segment and take steps to avoid disruptions. Key actions include: 

• Prioritize health care during allocation decisions and periods of constrained supply. 

• Provide earlier visibility into component transitions, product discontinuations, allocation decisions, and anticipated supply constraints. 

• Engage directly with medtech manufacturers to account for the sector’s longer product lifecycles and regulatory, quality, and patient-care obligations. 

• Incorporate health care-specific requirements into long-term supply planning and product transition decisions. 

Although medtech represents only a small share of global memory chip demand, targeted supplier action can help protect patient access and strengthen long-term resilience across both the memory chip and medical technology sectors. 

Abby Pratt is AdvaMed’s senior vice president for global strategy and analysis.